Retrospective Cohort Study
Copyright ©The Author(s) 2023.
World J Gastrointest Oncol. Oct 15, 2023; 15(10): 1784-1795
Published online Oct 15, 2023. doi: 10.4251/wjgo.v15.i10.1784
Table 1 Baseline characteristics of the study participants
Variables
Total, n = 500
Low-risk group, n = 194
Intermediate-risk group, n = 218
High-risk group, n = 88
P value
Age, median (IQR)68.9 (62.5, 75.9)69.1 (62.9, 75.2)68.6 (62.6, 76.2)69.0 (61.4, 76.8)0.93
Sex, n (%)0.459
    Male306 (61.2)117 (60.3)130 (59.6)59 (67)
    Female194 (38.8)77 (39.7)88 (40.4)29 (33)
CAT, n (%)0.254
    Non430 (86.0)161 (83)190 (87.2)79 (89.8)
    All CAT70 (14.0)33 (17)28 (12.8)9 (10.2)
    ATE11 (2.2)0 (0)6 (2.8)5 (5.7)
ECOG PS, n (%)0.053
    0-1449 (89.8)181 (93.3)194 (89)74 (84.1)
    ≥ 251 (10.2)13 (6.7)24 (11)14 (15.9)
Cancer type, n (%)< 0.001
    GC206 (41.2)0 (0)123 (56.4)83 (94.3)
    CRC294 (58.8)194 (100)95 (43.6)5 (5.7)
Adjuvant chemotherapy, n (%)0.069
    No306 (61.2)111 (57.2)132 (60.6)63 (71.6)
    Yes194 (38.8)83 (42.8)86 (39.4)25 (28.4)
Active cancer (AC), n (%)0.201
    Non-AC141 (28.2)57 (29.4)66 (30.3)18 (20.5)
    AC359 (71.8)137 (70.6)152 (69.7)70 (79.5)
Single or multiple primary tumor, n (%)0.95
    Single450 (90.0)174 (89.7)196 (89.9)80 (90.9)
    Multiple50 (10.0)20 (10.3)22 (10.1)8 (9.1)
Pathological type, n (%)< 0.001
    Well and mod317 (63.4)169 (87.1)120 (55)28 (31.8)
    Others169 (33.8)19 (9.8)95 (43.6)55 (62.5)
    Unknown14 (2.8)6 (3.1)3 (1.4)5 (5.7)
Primary site surgery, n (%)< 0.001
    No122 (24.4)19 (9.8)58 (26.6)45 (51.1)
    Yes378 (75.6)175 (90.2)160 (73.4)43 (48.9)
CVC placement, n (%)< 0.001
    No168 (33.6)46 (23.7)89 (40.8)33 (37.5)
    Yes332 (66.4)148 (76.3)129 (59.2)55 (62.5)
Opportunity for Diagnosis, n (%)0.714
    Asymptomatic495 (99.0)193 (99.5)215 (98.6)87 (98.9)
    Symptomatic5 (1.0)1 (0.5)3 (1.4)1 (1.1)
Thrombosis treatment, n (%)0.424
    No470 (94.0)179 (92.3)207 (95)84 (95.5)
    Yes30 (6.0)15 (7.7)11 (5)4 (4.5)